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ABSTRACT
OBJECTIVE: The objective of this evidence-based medicine (EBM) review was to determine
whether or not catheter ablation improves quality of life in patients with atrial fibrillation
compared to drug therapy.
STUDY DESIGN: Systematic review of three peer-reviewed studies published in the years 2018
and 2019. All three studies were published in English.
DATA SOURCES: Articles were selected based on their relevance to the clinical question.
Additionally, all three studies placed emphasis on patient-oriented outcomes. The studies were
selected via Pubmed and keyword searching. The first study selected and reviewed was an
observational cohort study, the second study was a multi-center open-label randomized
controlled trial (RCT), and the third and last study reviewed was an RCT with blinded outcome
evaluations.
OUTCOMES MEASURED: Participants quality of life was measured by using Medical
Outcomes Study 36-item Short Form Health Survey (SF-36), the Atrial Fibrillation Effect on
Quality of life (AFEQT) questionnaire, the Mayo AF-Specific Symptom Inventory (MAFSI)
questionnaire, and the Arrhythmia-specific questionnaire in Tachycardia and Arrhythmia
(ASTA).
RESULTS: The study conducted by Barmano et al. found a statistically significant improvement
in quality of life of those individuals receiving a catheter ablation (p < 0.01). The study
conducted by Blomstrom et al. found a significant and positive increase in the SF-36 scores of
patients receiving a catheter ablation as compared to the medication treatment group (p = 0.003).
Mark et al. found a significantly higher quality of life -- as measured by both the MAFSI and
AEFQT -- in patients receiving a catheter ablation as compared to a medication treatment group
(both p < 0.001).
CONCLUSION: The data presented in this systematic evidence-based medicine review
demonstrate a significant positive impact of catheter ablation on the quality of life in patients
with atrial fibrillation. While no study is without limitations, all three studies reviewed
confirmed a statistically significant improvement in quality of life. Future research studies
should continue to use randomized controlled trials as well as ensuring there is no crossover
between control and treatment groups.
KEY WORDS: Atrial fibrillation, catheter ablation, quality of life
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INTRODUCTION
Atrial fibrillation (AF) is the most common chronic arrhythmia and is associated with
increased morbidity and mortality if left untreated. It is estimated that about 10 million
Americans have AF; affecting approximately 9% of people over the age of 65.1 Consequences of
untreated AF include cerebral infarction, heart failure, LV dysfunction and myocardial ischemia.
Cerebral infarction, secondary to an embolizing thrombus, is possibly the most serious
consequence from untreated AF leading to significant morbidity and mortality.1 In addition to
being a burdensome medical condition to patients, it is also very costly to manage AF.
According to the American Heart Association, the annual cost of AF treatment in 2014 was
estimated to be 10.1 billion which was a 37% increase from 7.39 billion in 2007.2 Furthermore,
to emphasis the impact that AF has on the healthcare system, between 2007-2014 over 800,000
ED visits were for AF and AF is estimated to contribute to more than 80,000 annual deaths.”2
AF is characterized by disorganized and rapid atrial activation. It can occur secondary to
valvular heart disease, dilated cardiomyopathy, HTN, ASD, thyrotoxicosis and in some
individuals without any apparent cardiac disease.1 Acute alcohol excess or withdrawal can
trigger AF as well.1 Signs and symptoms of AF include dyspnea, hypotension, palpitations,
lightheadedness, syncope, chest pain, and peripheral edema. There is little unknown about AF,
plenty of research has been conducted on the condition. In the beginning of the disease course,
AF will present in a paroxysmal manner however over the course of the disease it likely becomes
the dominant rhythm.1
Treatment for AF is often very personalized as many patients have coexisting
comorbidities which could alter treatment options. Management of AF is well within the scope
of physician assistants in many specialties ranging from family medicine to cardiothoracic
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surgery. In hemodynamically stable patients, management of AF includes rate control via beta
blockers or calcium channel blockers, rhythm control via antiarrhythmic agents (potassium
channel blockers or sodium channel blockers), along with anti-coagulation with direct oral
anticoagulants (DOACs) or coumadin. With recurrent-symptomatic AF, treatment options
typically include antiarrhythmic agents, anti-coagulation and catheter ablation.
The medications utilized for treatment of AF have considerable side effects, including but
not limited to ventricular arrythmias, thyroid dysfunction, worsening asthma/COPD, sexual
dysfunction, and bleeding.1 Also, there is the chance of refractory/symptomatic AF despite
taking these medications, about 25-50% of AF cases treated with antiarrhythmic drugs will have
refractory symptoms within one year.3 Catheter ablation is a minimally invasive procedure which
destroys the irritable foci triggering the AF and minimizing the likelihood recurrence. The oneyear success rates for patients with paroxysmal AF is about 70-80% and 60-70% in patients with
persistent AF.3 Important to note, patients with AF refractory to catheter ablation experience less
burdensome AF symptoms compared to their antiarrhythmic counterparts.3 Catheter ablation is
not without risks. The most frequent serious complication of catheter ablation is cardiac
tamponade which occurs in slightly more than 1% of radiofrequency catheter ablations. 4 Some
other complications of this procedure include catheter entrapment, pulmonary vein stenosis,
phrenic nerve injury and perioperative thromboembolic events.4 This paper evaluates two
randomized control trials and one observational cohort study comparing the efficacy of catheter
ablation improving QOL in patients with AF compared to drug therapy.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not catheter
ablation improves quality of life in patients with atrial fibrillation compared to drug therapy.
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METHODS
To complete this selective EBM review, articles were selected based on being patient
oriented outcomes and relating to my clinical question. Studies were searched using PubMed and
were published in peer-reviewed journals. Keywords used to search for relevant articles included
“Atrial fibrillation”, “ablation” and “quality of life”. Articles related to humans and published
within the past 5 years were inclusion criteria for articles chosen. Studies published prior to 2014
and studies on animals were excluded from the article search. Statistics utilized in this review
include p-value. Table 1 displays the demographics and characteristics included in each chosen
article.
Two randomized control trials (RCTs) and one observational single-center cohort study
were utilized for this EBM review. The population of concern in these articles were patients with
AF, both paroxysmal and persistent. All three articles studied catheter ablation as the
intervention to the treatment groups. The treatment groups were compared to control groups
receiving pharmacologic therapies for treatment of AF. Quality of life is the outcome being
measured in all three studies.
OUTCOMES MEASURED
The outcome of interest measured for this EBM review is patient quality of life (QOL).
Quality of life was measured using patient questionnaires in all three studies. The ArrhythmiaSpecific questionnaire in Tachycardia and Arrhythmia (ASTA), utilized in the Barmano et al.
observational cohort study, assessed 9 items relating to symptom burden and 13 items relating to
health-related quality of life (HRQoL).5 ASTA scale scores range from 0-100, a higher score
reflects a higher symptom burden and worse effect on HRQoL from the arrhythmia. 5
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Table 1. Demographics & Characteristics of Included Studies
Study

Type

#
Age
Pts (yrs)
338 60.2
10.2

Inclusion
Criteria
-Age > 18 yrs
with
paroxysmal or
persistent
Afib; First
time
radiofrequency
ablation

Barmano5
(2018)

Observational
cohort study

Blomstrom6
(2019)

RCT with
blinded
evaluation of
outcomes

167 30-70
yrs

-Age 30-70;
Hx of
symptomatic
Afib for at
least 6 months;
Failure/intoler
ance to a
maximum of 1
antiarrhythmic
drug

Mark7
(2019)

RCT

220 Older
4
than
65;65
yrs or
young
er
with
at
least 1
risk
factor
for
stroke

-Episodes of
Afib over the
preceding 6
months; Be
over 18 y/o

Exclusion
Criteria
-Previous
catheter or
surgical Afib
ablation;
Previous/plann
ed heart
surgery; LV
EF <35%;
ACS during
past 3 months
-NYHA class
III-IV; LV EF
<35%;
Previous
ablation;
Ventricular
pacing
dependency;
Afib
secondary to
transient or
correctable
trigger
-Prior catheter
ablation; Class
IV CHF or
Angina;
Recent MI or
PCI;
Reversible
cause for Afib;
Dialysis
patients

W/
D
146

Interventions

12

Pulmonary vein
isolation ablation

236

Pulmonary vein
isolation ablation

Radiofrequency
ablation
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The Medical Outcomes Study 36-item Short Form Health Survey (SF-36), utilized in the RCT by
Blomstrom et al., is a 36-item questionnaire. From this questionnaire a score from 0 to 100 is
obtained, higher scores indicate greater health or well-being.6 The RCT conducted by Mark et
al., utilized both the Atrial Fibrillation Effect on Quality of life (AFEQT) questionnaire and the
Mayo AF-Specific Symptom Inventory (MAFSI) questionnaire. AFEQT is a 21-item QOL
questionnaire with scores ranging from 0 to 100, 0 being AF causing complete disability and 100
being AF causing no disability.7 MAFSI is a 10-item checklist with scores ranging from 0 to 40,
0 being no AF symptoms and 40 being most severe AF symptoms.5
RESULTS
In Barmano et al. observation single cohort study, 338 patients with AF were eligible for
radiofrequency ablation (RFA). 192 patients over the age of 18 undergoing their first
radiofrequency ablation for AF were included in this study. Patients were excluded if they had a
previous catheter or surgical AF ablation, had previous or planned heart surgery, LV EF <35% or
acute coronary syndrome in the past 3 months.5 Prior to the radiofrequency ablation, all included
participants underwent a TTE and EF was calculated. ASTA questionaries were collected at
baseline, 4 months and 1 year following the radiofrequency ablation. At baseline, the healthrelated quality of life scale (HRQoL) portion of the ASTA questionnaire averaged 36 points.
Four months following the radiofrequency ablation, the HRQoL score decreased to an average of
10. Ultimately, at 1 year follow up the HRQoL score decreased to an average of 0 signifying
most participants had no symptom burden from their AF. See Table 2 below. These results were
significant with a calculated Friedman’s test p -value < 0.001 from baseline to 1 year follow up.

Bland, Catheter Ablation and Quality of Life

6

Table 2. Health-Related QOL scores following radiofrequency ablation
Following RFA

Baseline

4 month F/u

1 year F/u

HRQoL Scale Score

36

10

0***

*p < .1. **p < .05. ***p < .01
Blomstrom et al. is a multicenter open-label randomized control trial assessing the quality
of life in AF patients following pulmonary vein isolation ablation compared to antiarrhythmic
medications.6 167 patients were eligible for this study. Patients were required to be 30-70 years
old, have a history of symptomatic AF for at least 6 months which was verified by ECG, and
failure of or intolerance to a maximum of 1 antiarrhythmic drug. Exclusion criteria included
NYHA class III-VI, LV EF <35, and AF secondary to a transient or correctable cause. Patients
were assigned using permuted block design with variable block size stratified by clinical site and
type of AF (paroxysmal vs persistent).6 Of the 167 eligible patients, 155 were randomized. 79
were randomized to the ablation group and 75 actually received the ablation. 76 were
randomized to the antiarrhythmic medication group and 74 patients actually received the
antiarrhythmic medication.
This study evaluated overall QOL using the SF-36 General Health questionnaire at
baseline and at 12 months. From baseline to 12 months, the ablation group improved
significantly more than the medication group. At baseline, the ablation scored 61.8 vs. the
medication group scoring 62.7. However, at 12 months, the mean change in the ablation
increased 11.9 points compared to 3.1 points in the medication group; resulting in a mean
treatment difference of 8.9 points. This is significant with a p -value = 0.003. See Table 3.
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Table 3. QOL scores at Baseline and 12 months in ablation vs. medication groups
SF-36 score

Baseline

12 months

Ablation Group

61.8

73.7

Medication Group

62.7

65.8

Mean Treatment Difference

-

8.9***

*p < .1. **p < .05. ***p < .01
The multicenter open-label randomized controlled trial conducted by Mark et al. included
2204 patients with a median age of 68 years; 1108 patents were randomly assigned to the
catheter ablation group and 1096 were randomized to the drug therapy group. Patients were
assigned using permuted block design with variable block size stratified by clinical site.7 Of the
1108 assigned to the catheter ablation group, 1002 completed the study (9.56% attrition rate). Of
the 1096 assigned to the drug therapy group 966 completed the study (11.86% attrition rate). For
both groups, the majority of the attrition rate was attributed to individuals withdrawing their
consent to the study. Both the inclusion and exclusion criteria for the study can be found in Table
1.
The study recorded the participant’s quality of life at months 3, 12, and then every 12
months following. At month 12, the mean AFEQT summary score was 5.3 points higher in the
catheter ablation group than the drug therapy group (86.4 vs. 80.9).7 These results were
statistically significant at the p < 0.001 level. At year 5, the catheter ablation group’s mean
AFEQT score was 3.4 points higher than the drug therapy group. Once again, these results were
statistically significant at the p < 0.001 level. All three component scores of the AFEQT favored
the catheter ablation group but the p values for the differences in component scores were not
reported.
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In terms of the MAFSI frequency score, at 12 months measurement also favored the
catheter ablation group with a difference of -1.7 points (11.9 vs 8.1).7 The difference was
significant at the p < 0.001 level. For follow ups, the frequency score difference was -1.4 also
favoring the catheter ablation group at the p < 0.001 level. The MAFSI severity score favored the
catheter ablation group at both 12-months (mean difference -1.5, p < 0.001) and the follow-up
intervals (mean difference -1.1, no p-value reported for follow ups.)
DISCUSSION
Atrial fibrillation is the most common chronic arrhythmia impacting approximately 9%
of people over the age of 65 and accounting for over 800,000 ED visits between 2005 and 2004
posing both a practical health risk as well as a financial and logistical burden to the health care
system.1,2 While one of the most common treatment options, drug therapy also results in
considerable side effects such as COPD, thyroid dysfunction, and/or ventricular arrhythmias.
Conversely, catheter ablation is a minimally invasive procedure with minimal, and infrequent,
side effects that minimizes the likelihood of recurrence in patients resulting in both a minimized
financial and logistical burden but also a potential increase in the quality of life experienced by
patients. However, this procedure would require prior authorization from insurance. As
mentioned above, catheter ablations could have unfavorable consequences, most common being
cardiac tamponade, but this is infrequent.4 The purpose of this selective evidence-based review
was to establish whether or not there was a demonstrated, statistically significant improvement of
the quality of life of patients when compared to those who received drug therapy.
While there were limitations in all three studies reviewed, none of these limitations
reached the point of diminishing the significant findings of each study. The limitations noted in
the cohort study by Barmano et al. was the lack of randomization and a comparable treatment
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group. For the randomized control trials conducted by Blomstrom et al. as well as Marks et al.,
the major limitation was the inability of the researchers to impose strict crossover restrictions on
the participants; therefore, a patient could feasibly receive both a catheter ablation as well as a
drug therapy throughout the course of the study. Despite these limitations all three studies
demonstrated statistically significant improvements in the quality of life of patients with AF who
received a catheter ablation.
CONCLUSION
Based on the results of all three studies reviewed above, catheter ablation shows
significant improvements in the quality of life of patients in the treatment of atrial fibrillation.
The cohort study conducted by Barmano et al. indicated a significant improvement in the quality
of life in individuals with AF who received a catheter ablation. The limitation of this study,
however, was the lack of a comparison group in the form of those patients who received
medicine as opposed to a catheter ablation. Despite this limitation, the studies’ results indicate
positive improvements for those patients who did receive a catheter ablation. Conversely, both
Blomstrom et al. and Marks et al. conducted multi location open-label randomized control trials
comparing patients receiving a catheter ablation and those treating AF with medication. Both
studies found statistically significant increases in the quality of life measures for the catheter
ablation groups as opposed to the medication groups. A limitation for both of these studies,
however, was the lack of strict guidelines preventing a patient from crossing over between the
catheter ablation and medication groups.
As demonstrated by the strong results reported in this selective evidence-based medicine
review, there is promising evidence that catheter ablation significantly improves the quality of
life in individuals with atrial fibrillation. Although, no study, including the ones reviewed, is
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without their limitations. The strength of the findings presented warrants continued research into
the impact of catheter ablation on improving patient quality of life. Future studies should
continue to be conducted as randomized control trials to produce valid conclusions as well as
stricter guidelines on preventing crossover of patients from the control to treatment group prior
to the conclusion of the study. In light of the strong evidence presented in the studies reviewed,
and the side effects associated with medication treatment of AF, the opportunity exists to explore
widening the usage of catheter ablation for individuals living with atrial fibrillation.
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